KR890004691A - 안과 제제물용 방부 시스템 - Google Patents

안과 제제물용 방부 시스템 Download PDF

Info

Publication number
KR890004691A
KR890004691A KR1019880011664A KR880011664A KR890004691A KR 890004691 A KR890004691 A KR 890004691A KR 1019880011664 A KR1019880011664 A KR 1019880011664A KR 880011664 A KR880011664 A KR 880011664A KR 890004691 A KR890004691 A KR 890004691A
Authority
KR
South Korea
Prior art keywords
nsaid
ophthalmic
volume
weight
formulation
Prior art date
Application number
KR1019880011664A
Other languages
English (en)
Other versions
KR950013754B1 (ko
Inventor
짜이 로저 퓨 쩡
엠·리다테 데보라
Original Assignee
허비히 폰 모르쯔
신텍스(미합중국) 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22256043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890004691(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 허비히 폰 모르쯔, 신텍스(미합중국) 인코포레이티드 filed Critical 허비히 폰 모르쯔
Publication of KR890004691A publication Critical patent/KR890004691A/ko
Priority to KR1019950024224A priority Critical patent/KR950013745B1/ko
Application granted granted Critical
Publication of KR950013754B1 publication Critical patent/KR950013754B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Detergent Compositions (AREA)

Abstract

내용 없음

Description

안과 제제물용 방부 시스템
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (27)

  1. 안과 치료에 유효한 양의 NSAID와, 사급 암모늄 방부제와, 안정화 양의 비이온성 에톡실화 옥틸페놀 계면 활성제와, 수용성 부형제로 되는 안과 NSAID제제물.
  2. 제1항에 있어서, 상기 사급 암모늄 방부제가 염화 벤즈알코늄인 안과 NSAID제제물.
  3. 제1항에 있어서, 상기 비이온성 에톨실화 옥틸페놀 계면활성제가 3:1 내지 40:1의 산화 에틸렌 대 옥틸페놀 몰비를 갖는 옥틸페녹시폴리(에틸렌옥시)에탄올인 안과 NSAID 제제물.
  4. 제3항에 있어서, 상기 비이온성 에톨실화 옥틸페놀 계면활성제가 Octoxynol 40인 안과 NSAID 제제물.
  5. 제4항에 있어서, 에데트산 이나트륨을 포함하는 안과 NSAID 제제물.
  6. 제1항에 있어서, 상기 NSAID가 케토롤락, 인도메타신, 플루르비프로펜 및 디클로페낙 또는 그의 이성질체, 제약상 허용되는 염 또는 에스테르류로 되는 군 중에서 선택되는 안과 NSAID 제제물.
  7. 제6항에 있어서, 상기 NSAID가 Ketorolac Tromethamine인 안과 NSAID 제제물.
  8. 제6항에 있어서, 상기 NSAID가 케토롤락 또는 그의 제약상 허용되는 염류의 (ι)-이성체인 안과 NSAID 제제물.
  9. 제1항에 있어서, NSAID 0.001% 내지 10.0%(중량/용적), 방부제 0.001% 내지 1.0%(중량/용적), 계면활성제 0.001% 내지 1.0%(중량/용적)와, 정제수 100%까지 충분량으로 되는 안과 NSAID 제제물.
  10. 제9항에 있어서, 상기 방부제가 염화 벤즈 알코늄인 안과 NSAID 제제물.
  11. 제10항에 있어서, 상기 계면활성제가 Octoxynol 40인 안과 NSAID 제제물.
  12. 제11항에 있어서, 상기 NSAID가 Ketorolac Tromethamine인 안과 NSAID 제제물.
  13. 제9항에 있어서, 킬레이트화제 0.01% 내지 1.0%(중량/용적) 강장제 누액과 등장 상태를 얻기에 충분량과, 1N NaOH 또는 1N HCl pH를 6.0 내지 8.0로 조절하기에 충분량을 함유하는 안과 NSAID 제제물.
  14. 제13항에 있어서, NSAID 0.50%(중량/용적), BAC(50% 수용액) 0.02%(중량/용적), Octoxynol 40(70% 수용액) 0.01%(중량/용적), EDTA Na20.10%(중량/용적), NaCl 0.79%(중량/용적), 1N NaOH 또는 1N HCl pH를 7.4 ±0.4로 조절하기에 충분량과 정제수 100%까지 충분량으로 되는 안과 NSAID 제제물.
  15. 제14항에 있어서, 상기 NSAID가 Ketorolac Tromethamine인 안과 NSAID 제제물.
  16. 안과 치료에 유효한 양의 NSAID, 사급 암모늄, 방부제, 안정화 양의 비이온성 계면활성제가 수용성 부형제로 되는 제제물을 안과 질환에 걸린 포유동물에 투여하는 것으로 되는 안과 질환 치료방법.
  17. 제16항에 있어서, 상기 방부제가 염화 벤즈알코늄인 안과 질환 치료방법.
  18. 제17항에 있어서, 상기 계면활성제가 Octoxynol 40인 안과 질환 치료방법.
  19. 제16항에 있어서, 상기 NSAID가 케토롤락, 인도메타신, 플루르비프로펜 및 디클로페낙 또는 그의 이성질체, 제약상 허용되는 염 또는 에스테르류인 안과 질환 치료방법.
  20. 제20항에 있어서, 상기 NSAID가 Ketorolac Tromethamine인 안과 질환 치료방법.
  21. 제20항에 있어서, 상기 안과 NSAID 제제물이 Ketorolac Tromethamine 0.50%(중량/용적), BAC(50% 수용액) 0.02%(중량/용적), Octoxynol 40(70% 수용액) 0.01%(중량/용적), EDTA Na20.10%(중량/용적), NaCl 0.79%(중량/용적), 1N NaOH 또는 1N HCl pH를 7.4 ±0.4로 조절하기에 충분량과 정제수 100%까지 충분량으로 되는 안과 질환 치료방법.
  22. 사급 암모늄 방부제와 안정화 양의 비이온성 에톡실화 옥틸페놀 계면활성제로 되는, 안과학적으로 허용되는 카르복실기 함유 약제용 항균적으로 유효한 방부 시스템.
  23. 제22항에 있어서, 상기 방부제가 염화 벤즈알코늄이고, 상기 계면활성제가 Octoxynol 40인 방부 시스템.
  24. 제1항에 의한 제제물의 안과 염증 질환 치료 또는 예방 용도.
  25. 제22항에 있어서, 방부 시스템의 안과 염증 질환 치료 또는 예방용도.
  26. NSAID 0.001% 내지 10.0%(중량/용적), 방부제 0.010% 내지 1.0%(중량/용적), 비이온성 에톡실화 옥틸페놀 계면활성제 0.001% 내지 1.0%(중량/용적)와, 정제수 100%까지 충분량을 혼합하는 것으로 되는 안과 NSAID 제제물의 제조방법.
  27. 제26항에 있어서, 킬레이트화제 0.01% 내지 1.0%용적(중량/용적) 강장제 누액과 등장 상태를 얻기에 충분량과, 1N NaOH 또는 1N HCl pH를 6.0 내지 8.0로 조절하기에 충분량을 추가로 혼합하는 것으로 되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880011664A 1987-09-11 1988-09-09 안과용 비스테로이드계 소염제제 KR950013754B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950024224A KR950013745B1 (ko) 1987-09-11 1995-08-05 안과 제제용 방부 시스템

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9617387A 1987-09-11 1987-09-11
US096,173 1987-09-11
US07/096,173 1987-09-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019950024224A Division KR950013745B1 (ko) 1987-09-11 1995-08-05 안과 제제용 방부 시스템

Publications (2)

Publication Number Publication Date
KR890004691A true KR890004691A (ko) 1989-05-09
KR950013754B1 KR950013754B1 (ko) 1995-11-15

Family

ID=22256043

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880011664A KR950013754B1 (ko) 1987-09-11 1988-09-09 안과용 비스테로이드계 소염제제

Country Status (17)

Country Link
EP (1) EP0306984B1 (ko)
JP (1) JPH0696542B2 (ko)
KR (1) KR950013754B1 (ko)
AT (1) ATE74750T1 (ko)
AU (1) AU626798B2 (ko)
CA (1) CA1328614C (ko)
DE (1) DE3870111D1 (ko)
DK (1) DK174702B1 (ko)
FI (1) FI94924C (ko)
HK (1) HK27894A (ko)
HU (2) HU199072B (ko)
IE (1) IE60717B1 (ko)
IL (1) IL87724A (ko)
NO (1) NO175404C (ko)
NZ (1) NZ226100A (ko)
PH (1) PH25422A (ko)
ZA (1) ZA886757B (ko)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5414011A (en) * 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
ES2053161T3 (es) * 1989-09-21 1994-07-16 Ciba Vision Ag Composiciones antimicrobianas.
IL95942A0 (en) * 1989-10-13 1991-07-18 Syntex Inc Collagen-containing ophthalmic formulation
CA2077693C (en) * 1990-03-16 1997-03-04 Gary Robert Kelm Use of ketorolac for treatment of periodontal disease
US5464609A (en) * 1990-03-16 1995-11-07 The Procter & Gamble Company Use of ketorolac for treatment of oral diseases and conditions
US5422073A (en) * 1990-12-27 1995-06-06 Allergan, Inc. Method and composition for disinfecting contact lenses
US5227152A (en) * 1991-04-09 1993-07-13 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5093105A (en) * 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5306482A (en) * 1991-04-09 1994-04-26 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
CA2179147A1 (en) * 1993-12-17 1995-06-22 Gerald D. Cagle Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
ES2079320B1 (es) * 1994-05-17 1996-10-16 Cusi Lab Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
WO1995033456A2 (en) * 1994-06-07 1995-12-14 Telor Ophthalmic Pharmaceuticals, Inc. Reducing intraocular pressure using aryloxy- and aryl-acetic acids
CA2201134A1 (en) * 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
CA2210749C (en) * 1995-01-20 2001-04-10 Wakamoto Pharmaceutical Co., Ltd. Anti-inflammatory eye drop
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
TW434023B (en) * 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
MX9701946A (es) * 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
DE19729879C2 (de) * 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
JP2006111636A (ja) * 1997-12-26 2006-04-27 Astellas Pharma Inc 徐放性医薬組成物
BR0008674A (pt) * 1999-03-02 2002-02-13 Vitreo Retinal Technologies In Método para tratar ou prevenir a proliferação de fibroblastos dentro do olho, tratar ou prevenir a neovascularização de tecidos oculares, acelerar a clarificação do sangue hemorrágico do humor vìtreo, causar a dissolução não-enzimática da interface hialóide e/ou causar a separação ou a desinserção do vìtreo posterior
DE19918324A1 (de) * 1999-04-22 2000-10-26 Mann Gerhard Chem Pharm Fab Pharmazeutische Zusammensetzung wirksam gegen durch Bakterien, Viren, Pilze, Hefen und Protozoen verursachte Krankheitszustände
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
EP1586316B1 (en) 2003-01-21 2008-04-30 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US8008338B2 (en) 2003-06-03 2011-08-30 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
PL1654002T5 (pl) 2003-08-07 2014-06-30 Allergan Inc Kompozycje do dostarczania środków terapeutycznych do oczu
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20050261243A1 (en) * 2004-04-21 2005-11-24 Peyman Gholam A Antiprostaglandins for the treatment of ocular pathologies
US9161905B2 (en) * 2005-01-12 2015-10-20 Ocular Research Of Boston, Inc. Dry eye treatment
US9192571B2 (en) 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
JP5559339B2 (ja) 2009-10-12 2014-07-23 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物のための容器
CA2791805A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
JP2013082682A (ja) * 2011-09-29 2013-05-09 Senju Pharmaceut Co Ltd 亜塩素酸塩を含有する水性製剤
CN110448530A (zh) * 2018-05-07 2019-11-15 北京蓝丹医药科技有限公司 一种氟比洛芬酯注射液

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087538A (en) * 1976-09-09 1978-05-02 Merck & Co., Inc. Ophthalmic suspensions
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
ATE57472T1 (de) * 1984-03-14 1990-11-15 Jerome Corbiere Verfahren zum loesen von wirksubstanzen und auf diese weise erhaltene arzneimittel.

Also Published As

Publication number Publication date
IE60717B1 (en) 1994-08-10
DE3870111D1 (de) 1992-05-21
FI884160A0 (fi) 1988-09-09
ATE74750T1 (de) 1992-05-15
HUT47839A (en) 1989-04-28
FI94924B (fi) 1995-08-15
HU199072B (en) 1990-01-29
KR950013754B1 (ko) 1995-11-15
DK505688A (da) 1989-03-12
IL87724A (en) 1992-01-15
HK27894A (en) 1994-03-31
JPH0696542B2 (ja) 1994-11-30
EP0306984A1 (en) 1989-03-15
ZA886757B (en) 1990-05-30
DK174702B1 (da) 2003-09-29
AU2204288A (en) 1989-03-16
FI94924C (fi) 1995-11-27
HU210610A9 (en) 1995-05-29
DK505688D0 (da) 1988-09-09
CA1328614C (en) 1994-04-19
NO175404C (no) 1994-10-12
NO884020L (no) 1989-03-13
IL87724A0 (en) 1989-02-28
NO175404B (no) 1994-07-04
AU626798B2 (en) 1992-08-13
IE882740L (en) 1989-03-11
EP0306984B1 (en) 1992-04-15
PH25422A (en) 1991-07-01
JPH01104023A (ja) 1989-04-21
NZ226100A (en) 1990-12-21
NO884020D0 (no) 1988-09-09
FI884160A (fi) 1989-03-12

Similar Documents

Publication Publication Date Title
KR890004691A (ko) 안과 제제물용 방부 시스템
KR900013951A (ko) 안약용 방부제
US5110493A (en) Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US5558876A (en) Topical ophthalmic acidic drug formulations
CA2180554C (en) Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6107343A (en) Ophthalmic and aural compositions containing diclofenac potassium
EP1553953A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
KR910007511A (ko) 콜라겐 함유 안약 제형
US6281224B1 (en) Pranoprofen eyedrops containing organic amine
ES2685023T3 (es) Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
JPS60184013A (ja) 点眼剤
TW201322982A (zh) 用於治療前眼疾病之藥劑，該藥劑包含瑞巴派特及眼淚保持劑
CA2189424C (en) Non-steroidal anti-inflammatory ophthalmic suspensions
JPS58174309A (ja) 消炎点眼剤
JPH0717863A (ja) プラノプロフェン点眼液
AU2017235979B2 (en) Non-irritating ophthalmic povidone-iodine compositions
JPH05505605A (ja) 眼圧低下剤としての５―トランスプロスタグランジンＦ↓２αの使用
US20070254939A1 (en) Formulations Containing Amide Derivatives of Carboxylic Acid NSAIDS for Topical Administration to the Eye
Tolman et al. Inhibition of prostaglandin-mediated ocular inflammatory responses by 4-biphenylacetic acid.
JPH10203979A (ja) チアプロフェン酸を含有する抗眼炎症剤
US5457126A (en) Use of lodoxamide to treat ophthalmic allergic conditions
JPH05504962A (ja) 眼圧低下剤としてのプロスタグランジンＦ↓３αの使用
JP2000247906A (ja) グリセリド誘導体含有点眼剤
JPS61260020A (ja) 眼部局所投与剤
JPH09100233A (ja) 角膜保護剤

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20091012

Year of fee payment: 15

EXPY Expiration of term